Regulatory alerts
New treatment for rare inherited liver condition not cost-effective, says NICE in draft guidance
Lumasiran, which has been available via the MHRA’s EAMS, was not recommended for primary hyperoxaluria type 1 in NICE draft guidance.
Drug Safety Update: denosumab 60mg (Prolia)
The treatment should not be used in patients under 18 years due to the risk of serious hypercalcaemia.
